SCP2 and neoplasm: Consistent with in vivo results that circIKBKB-ASO treatment decreased the number of TRAP+-osteoclasts along the bone-tumor interface in SCP2/mice (Fig. 1g), silencing circIKBKB significantly reduced the inductive effect of CM/SCP2 cells on osteoclastogenesis, as indicated by reduced TRAP+-multinucleated mature osteoclasts and TRAP enzymatic activity, as well as decreased the expression of osteoclastogenesis-related markers (Fig. S3a-c).